메뉴 건너뛰기




Volumn 21, Issue 8, 2008, Pages 852-859

Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; AZILSARTAN; CANDESARTAN; CANDESARTAN HEXETIL; EPROSARTAN; EXP 3179; IRBESARTAN; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; URIC ACID; VALSARTAN;

EID: 47749111284     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.202     Document Type: Review
Times cited : (25)

References (68)
  • 3
    • 38049049272 scopus 로고    scopus 로고
    • Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state
    • Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, Matsuo Y, Karnik SS, Saku K. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22:139-146.
    • (2008) Mol Endocrinol , vol.22 , pp. 139-146
    • Miura, S.1    Kiya, Y.2    Kanazawa, T.3    Imaizumi, S.4    Fujino, M.5    Matsuo, Y.6    Karnik, S.S.7    Saku, K.8
  • 4
    • 20444418116 scopus 로고    scopus 로고
    • Molecular-specific effects of angiotensin II antagonists: Clinical relevance to treating hypertension?
    • Reid JL. Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? J Renin Angiotensin Aldosterone Syst 2005; 6:15-24.
    • (2005) J Renin Angiotensin Aldosterone Syst , vol.6 , pp. 15-24
    • Reid, J.L.1
  • 5
    • 34547489857 scopus 로고    scopus 로고
    • Uric acid reduction: A new paradigm in the management of cardiovascular risk?
    • Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007; 14:1879-1886.
    • (2007) Curr Med Chem , vol.14 , pp. 1879-1886
    • Dawson, J.1    Quinn, T.2    Walters, M.3
  • 6
    • 18244367869 scopus 로고    scopus 로고
    • Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: Prospective study and meta-analysis
    • Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005; 2:e76.
    • (2005) PLoS Med , vol.2
    • Wheeler, J.G.1    Juzwishin, K.D.2    Eiriksdottir, G.3    Gudnason, V.4    Danesh, J.5
  • 8
    • 1542510891 scopus 로고    scopus 로고
    • Uric acid: Role in cardiovascular disease and effects of losartan
    • Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20:369-379.
    • (2004) Curr Med Res Opin , vol.20 , pp. 369-379
    • Alderman, M.1    Aiyer, K.J.2
  • 9
    • 40549090278 scopus 로고    scopus 로고
    • Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers
    • Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, Tamai I. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 2008; 25:639-646.
    • (2008) Pharm Res , vol.25 , pp. 639-646
    • Sato, M.1    Iwanaga, T.2    Mamada, H.3    Ogihara, T.4    Yabuuchi, H.5    Maeda, T.6    Tamai, I.7
  • 10
    • 33845887252 scopus 로고    scopus 로고
    • Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter
    • Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320:211-217.
    • (2007) J Pharmacol Exp Ther , vol.320 , pp. 211-217
    • Iwanaga, T.1    Sato, M.2    Maeda, T.3    Ogihara, T.4    Tamai, I.5
  • 11
    • 0028593665 scopus 로고
    • Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension
    • Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7:1035-1040.
    • (1994) Am J Hypertens , vol.7 , pp. 1035-1040
    • Sweet, C.S.1    Bradstreet, D.C.2    Berman, R.S.3    Jallard, N.4    Saenz, A.5    Weidler, D.J.6
  • 12
    • 33847421488 scopus 로고    scopus 로고
    • Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    • Devereux RB, Dahlöf B. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Curr Med Res Opin 2007; 23:443-457.
    • (2007) Curr Med Res Opin , vol.23 , pp. 443-457
    • Devereux, R.B.1    Dahlöf, B.2
  • 14
    • 0015829488 scopus 로고
    • Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis
    • Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180:1332-1339.
    • (1973) Science , vol.180 , pp. 1332-1339
    • Ross, R.1    Glomset, J.A.2
  • 15
    • 0028970042 scopus 로고
    • Cell biology of atherosclerosis
    • Ross R. Cell biology of atherosclerosis. Ann Rev Physiol 1995; 57:791-804.
    • (1995) Ann Rev Physiol , vol.57 , pp. 791-804
    • Ross, R.1
  • 16
    • 33846362954 scopus 로고    scopus 로고
    • Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system
    • Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97.
    • (2007) Am J Physiol Cell Physiol , vol.292
    • Mehta, P.K.1    Griendling, K.K.2
  • 17
    • 0026499001 scopus 로고
    • Factors controlling smooth-muscle cell proliferation
    • Reidy MA. Factors controlling smooth-muscle cell proliferation. Arch Pathol Lab Med 1992; 116:1276-1280.
    • (1992) Arch Pathol Lab Med , vol.116 , pp. 1276-1280
    • Reidy, M.A.1
  • 18
    • 42049108222 scopus 로고    scopus 로고
    • Inhibition of cardiovascular cell proliferation by angiotensin receptor antagonists: Are all molecules the same?
    • Benson SC, Iguchi R, Ho CI, Yamamoto K, Kurtz TW. Inhibition of cardiovascular cell proliferation by angiotensin receptor antagonists: are all molecules the same? J Hypertens 2008; 26:973-980.
    • (2008) J Hypertens , vol.26 , pp. 973-980
    • Benson, S.C.1    Iguchi, R.2    Ho, C.I.3    Yamamoto, K.4    Kurtz, T.W.5
  • 20
    • 2442451618 scopus 로고    scopus 로고
    • Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity
    • Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004; 109:2054-2057.
    • (2004) Circulation , vol.109 , pp. 2054-2057
    • Schupp, M.1    Janke, J.2    Clasen, R.3    Unger, T.4    Kintscher, U.5
  • 21
    • 0035146287 scopus 로고    scopus 로고
    • Control of vascular cell proliferation and migration by PPAR-γ: A new approach to the macrovascular complications of diabetes
    • Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001; 24:392-397.
    • (2001) Diabetes Care , vol.24 , pp. 392-397
    • Hsueh, W.A.1    Jackson, S.2    Law, R.E.3
  • 22
    • 0026689544 scopus 로고
    • DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors
    • Liu EC, Hedberg A, Goldenberg HJ, Harris DN, Webb ML. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 1992; 44:89-99.
    • (1992) Prostaglandins , vol.44 , pp. 89-99
    • Liu, E.C.1    Hedberg, A.2    Goldenberg, H.J.3    Harris, D.N.4    Webb, M.L.5
  • 23
    • 0030911212 scopus 로고    scopus 로고
    • Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries
    • Li P, Ferrario CM, Brosnihan KB. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997; 281:1065-1070.
    • (1997) J Pharmacol Exp Ther , vol.281 , pp. 1065-1070
    • Li, P.1    Ferrario, C.M.2    Brosnihan, K.B.3
  • 24
    • 0033981547 scopus 로고    scopus 로고
    • Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation
    • Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000; 292:238-246.
    • (2000) J Pharmacol Exp Ther , vol.292 , pp. 238-246
    • Li, P.1    Fukuhara, M.2    Diz, D.I.3    Ferrario, C.M.4    Brosnihan, K.B.5
  • 26
    • 0035072743 scopus 로고    scopus 로고
    • The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo
    • Fukuhara M, Neves LA, Li P, Diz DI, Ferrario CM, Brosnihan KB. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo. J Hypertens 2001; 19(3 Pt 2):561-566.
    • (2001) J Hypertens , vol.19 , Issue.3 PART 2 , pp. 561-566
    • Fukuhara, M.1    Neves, L.A.2    Li, P.3    Diz, D.I.4    Ferrario, C.M.5    Brosnihan, K.B.6
  • 32
    • 0038101440 scopus 로고    scopus 로고
    • Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites
    • Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J Med Chem 2003; 46:2261-2270.
    • (2003) J Med Chem , vol.46 , pp. 2261-2270
    • Schmidt, B.1    Schieffer, B.2
  • 33
    • 25444531421 scopus 로고    scopus 로고
    • Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: Angiotensin II type 1 receptor-independent effects of EXP3179
    • Watanabe T, Suzuki J, Yamawaki H, Sharma VK, Sheu SS, Berk BC. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. Circulation 2005; 112:1798-1805.
    • (2005) Circulation , vol.112 , pp. 1798-1805
    • Watanabe, T.1    Suzuki, J.2    Yamawaki, H.3    Sharma, V.K.4    Sheu, S.S.5    Berk, B.C.6
  • 34
    • 34249325904 scopus 로고    scopus 로고
    • Atherosclerosis and oxidant stress: The end of the road for antioxidant vitamin treatment?
    • Thomson MJ, Puntmann V, Kaski JC. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? Cardiovasc Drugs Ther 2007; 21:195-210.
    • (2007) Cardiovasc Drugs Ther , vol.21 , pp. 195-210
    • Thomson, M.J.1    Puntmann, V.2    Kaski, J.C.3
  • 35
    • 34447315837 scopus 로고    scopus 로고
    • Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker
    • Shao J, Nangaku M, Inagi R, Kato H, Miyata T, Matsusaka T, Noiri E, Fujita T. Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 2007; 25:1643-1649.
    • (2007) J Hypertens , vol.25 , pp. 1643-1649
    • Shao, J.1    Nangaku, M.2    Inagi, R.3    Kato, H.4    Miyata, T.5    Matsusaka, T.6    Noiri, E.7    Fujita, T.8
  • 37
    • 33750913676 scopus 로고    scopus 로고
    • Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-γ activation
    • Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-γ activation. Diabetologia 2006; 49:3094-3099.
    • (2006) Diabetologia , vol.49 , pp. 3094-3099
    • Yoshida, T.1    Yamagishi, S.2    Nakamura, K.3    Matsui, T.4    Imaizumi, T.5    Takeuchi, M.6    Koga, H.7    Ueno, T.8    Sata, M.9
  • 39
    • 36448932405 scopus 로고    scopus 로고
    • Progressive increase in infarct size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid
    • Whitehead SN, Cheng G, Hachinski VC, Cechetto DF. Progressive increase in infarct size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid. Stroke 2007; 38:3245-3250.
    • (2007) Stroke , vol.38 , pp. 3245-3250
    • Whitehead, S.N.1    Cheng, G.2    Hachinski, V.C.3    Cechetto, D.F.4
  • 40
    • 19244365650 scopus 로고    scopus 로고
    • Thiazolidinediones
    • Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
    • (2004) N Engl J Med , vol.351 , pp. 1106-1118
    • Yki-Jarvinen, H.1
  • 42
    • 10344249378 scopus 로고    scopus 로고
    • Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system
    • Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22:2253-2261.
    • (2004) J Hypertens , vol.22 , pp. 2253-2261
    • Kurtz, T.W.1    Pravenec, M.2
  • 45
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 46
    • 26244453309 scopus 로고    scopus 로고
    • Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
    • Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
  • 47
    • 34548590934 scopus 로고    scopus 로고
    • Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
    • Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180-1188.
    • (2007) JAMA , vol.298 , pp. 1180-1188
    • Lincoff, A.M.1    Wolski, K.2    Nicholls, S.J.3    Nissen, S.E.4
  • 49
    • 0030602866 scopus 로고    scopus 로고
    • The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
    • Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302:93-109.
    • (1996) Biochim Biophys Acta , vol.1302 , pp. 93-109
    • Schoonjans, K.1    Staels, B.2    Auwerx, J.3
  • 53
  • 54
    • 33646148948 scopus 로고    scopus 로고
    • Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis
    • Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47:1003-1009.
    • (2006) Hypertension , vol.47 , pp. 1003-1009
    • Sugimoto, K.1    Qi, N.R.2    Kazdova, L.3    Pravenec, M.4    Ogihara, T.5    Kurtz, T.W.6
  • 55
    • 4344569280 scopus 로고    scopus 로고
    • Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study
    • Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27:457-464.
    • (2004) Hypertens Res , vol.27 , pp. 457-464
    • Derosa, G.1    Ragonesi, P.D.2    Mugellini, A.3    Ciccarelli, L.4    Fogari, R.5
  • 57
    • 14644444519 scopus 로고    scopus 로고
    • Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences
    • Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28:757-758.
    • (2005) Diabetes Care , vol.28 , pp. 757-758
    • Miura, Y.1    Yamamoto, N.2    Tsunekawa, S.3    Taguchi, S.4    Eguchi, Y.5    Ozaki, N.6    Oiso, Y.7
  • 59
    • 33745511931 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications
    • Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vasc Pharmacol 2006; 45:19-28.
    • (2006) Vasc Pharmacol , vol.45 , pp. 19-28
    • Touyz, R.M.1    Schiffrin, E.L.2
  • 60
  • 61
    • 33747402467 scopus 로고    scopus 로고
    • Telmisartan inhibits β2-integrin MAC-1 expression in human T-lymphocytes
    • Link A, Lenz M, Legner D, Bohm M, Nickenig G. Telmisartan inhibits β2-integrin MAC-1 expression in human T-lymphocytes. J Hypertens 2006; 24:1891-1898.
    • (2006) J Hypertens , vol.24 , pp. 1891-1898
    • Link, A.1    Lenz, M.2    Legner, D.3    Bohm, M.4    Nickenig, G.5
  • 62
    • 36248953701 scopus 로고    scopus 로고
    • Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients
    • Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, Lim SY, Lim DS. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 2007; 100:1625-1629.
    • (2007) Am J Cardiol , vol.100 , pp. 1625-1629
    • Hong, S.J.1    Shim, W.J.2    Choi, J.I.3    Joo, H.J.4    Shin, S.Y.5    Park, S.M.6    Lim, S.Y.7    Lim, D.S.8
  • 64
    • 39749201501 scopus 로고    scopus 로고
    • Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system. role of angiotensin II type 1 receptor and peroxisome proliferator activated receptor γ signaling during endothelial aging
    • Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Tager M, Bode-Boger SM. Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system. role of angiotensin II type 1 receptor and peroxisome proliferator activated receptor γ signaling during endothelial aging. Hypertension 2008; 51:696-703.
    • (2008) Hypertension , vol.51 , pp. 696-703
    • Scalera, F.1    Martens-Lobenhoffer, J.2    Bukowska, A.3    Lendeckel, U.4    Tager, M.5    Bode-Boger, S.M.6
  • 65
    • 42049107348 scopus 로고    scopus 로고
    • Telmisartan, ramipril, or both in patients at high risk for vascular events
    • Investigators TO
    • Investigators TO. Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med 2008; 358:1547-1559.
    • (2008) New Engl J Med , vol.358 , pp. 1547-1559
  • 66
    • 34247581728 scopus 로고    scopus 로고
    • TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation
    • Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20:579-586.
    • (2007) Am J Hypertens , vol.20 , pp. 579-586
    • Iwai, M.1    Chen, R.2    Imura, Y.3    Horiuchi, M.4
  • 67
    • 0030480485 scopus 로고    scopus 로고
    • Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres
    • Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 1996; 39:5228-5235.
    • (1996) J Med Chem , vol.39 , pp. 5228-5235
    • Kohara, Y.1    Kubo, K.2    Imamiya, E.3    Wada, T.4    Inada, Y.5    Naka, T.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.